MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
Study conduct The trial was conducted from 19 May 2022 to 2 March 2026 (data cutoff date) in…
Browsing Tag